BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its ...
A complement blood test measures how well complement proteins in your blood support immune defense. The complement system helps antibodies fight germs and clear foreign substances. Complement testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results